EBV-targeted MS vaccine trial opens recruitment in UK

Credit: Getty Images/Remains

By Jane Kirby, PA

A Phase 2 clinical trial is now recruiting to evaluate whether an investigational mRNA vaccine against Epstein-Barr virus may reduce disease activity in patients with multiple sclerosis.

The Horizon trial will enroll 180 participants internationally, with up to 10 UK sites participating. The study is led by the University of Edinburgh's MS and Neuroimmunology Hub at the Anne Rowling Clinic, with sponsorship from Moderna.